This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wang SA, Hasserjian RP. Acute erythroleukemias, acute megakaryoblastic leukemias, and reactive mimics: a guide to a number of perplexing entities. Am J Clin Pathol. 2015;144:44–60.
Daniels L, Guerti K, Vermeulen K, De Raeve H, Van Assche E, Van de Velde AL, et al. Acute myeloid leukaemia of mixed megakaryocytic and erythroid origin: a case report and review of the literature. Acta Clin Belg. 2007;62:308–14.
Jang W, Kim M, Lee JW, Chung NG. Acute myeloid leukemia of mixed megakaryocytic and erythroid origin following chemotherapy for T-cell lymphoblastic lymphoma. Int J Hematol. 2014;99:213–4.
Tang JZ, Carmichael CL, Shi W, Metcalf D, Ng AP, Hyland CD, et al. Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. Proc Natl Acad Sci USA. 2013;110:6091–6.
Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci USA. 2014;111:E5401–5410.
Zhang J, Kong G, Rajagopalan A, Lu L, Song J, Hussaini M, et al. p53−/− synergizes with enhanced Nras G12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia. Blood. 2017;129:358–70.
Goldberg L, Tijssen MR, Birger Y, Hannah RL, Kinston SJ, Schutte J, et al. Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia. Blood. 2013;122:2694–703.
Li Y, Schwab C, Ryan S, Papaemmanuil E, Robinson HM, Jacobs P, et al. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature. 2014;508:98–102.
Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2009;106:9414–8.
Arulogun SO, Choong H-L, Taylor D, Ambrosoli P, Magor G, Irving IM, et al. JAK1 somatic mutation in a myeloproliferative neoplasm. Haematologica. 2017;102:e324–e327.
Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115:3589–97.
Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23:905–11.
Chen E, Schneider RK, Breyfogle LJ, Rosen EA, Poveromo L, Elf S, et al. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood. 2015;125:327–35.
Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105:973–7.
Abdulkarim K, Girodon F, Johansson P, Maynadie M, Kutti J, Carli PM, et al. AML transformation in 56 patients with Ph- MPD in two well defined populations. Eur J Haematol. 2009;82:106–11.
Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123:2220–8.
Acknowledgements
We thank Janine Pichardo and Jeeyeon Baik for their administrative help. This study was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. WX is supported by a startup fund from Department of Pathology at the Memorial Sloan Kettering Cancer Center.
Author contributions:
WX and DCP conceived the study, performed the experiments, and wrote the paper. RR, YZ, RC, AAJ, MA, and MR performed the experiments. All the authors approved the final version of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Xiao, W., Rampal, R., Zhang, Y. et al. JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation. Leukemia 32, 1842–1845 (2018). https://doi.org/10.1038/s41375-018-0145-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-018-0145-6